- Improved entecavir intermediate synthesis process and improved entecavir synthesis process
-
The invention discloses an improved entecavir intermediate synthesis process and an improved entecavir synthesis process, and relates to the technical field of drug synthesis. The invention disclosesan improved entecavir intermediate synthesis process. In the synthesis process of an amino protection reaction product, amino protecting groups are added in batches; and the ratio of the reaction rawmaterials is optimized, so that the problems of long reaction time and relatively low amino protection reaction yield due to adoption of a one-time complete feeding mode in an existing synthesis modeare solved, the synthesis time of an amino protection reaction product is shortened to 50-70 minutes, and the obtained product is high in yield and purity. According to the improved entecavir synthesis process, in the amino protection reaction product synthesis process, reaction conditions are effectively optimized, and the purity of obtained entecavir reaches 99% or above.
- -
-
-
- Synthetic method of entecavir intermediate
-
The invention relates to a synthetic method of an entecavir intermediate. In particular, the present invention relates to the synthesis of compounds represented in the formula N7 by using TiCl4 and Ti(OiPr)4 as Lewis acids.
- -
-
Paragraph 0010; 0029-0040
(2020/02/14)
-
- Entecavir industrial preparation method (by machine translation)
-
The invention discloses entecavir industrial preparation method, which belongs to the technical field of organic synthesis. Including: Nysted reagent and intermediate VIII reaction, after the reaction is finished adding quenching fluid and holding the reaction system pH value of 7.0 - 8.5, obtained after the completion of reaction intermediates IX; intermediate IX react with hydrochloric acid, after the reaction is finished by adding the extractant and adjust pH value to 6.5 - 7.0, taking organic phase concentrated to 1/15 - 1/10 volume, crystallization, solid-liquid separation to obtain the intermediate X; intermediate with boron trichloride in dichloromethane in the X reaction, intermediate X with boron trichloride in a molar ratio of 1:5 - 10, the reaction temperature is - 30 — - 20 °C, after the reaction is finished cooling to - 30 °C following, dripping methanol, after the completion of the dropping the evaporation and once again by adding methanol, concentrated under reduced pressure, dryness and add into the water with the organic solvent of the extractant B, [...], adjust pH value to 6.5 - 7.0, concentrated, refine to get entecavir. (by machine translation)
- -
-
Paragraph 0028; 0029; 0030; 0031; 0032; 0033; 0034
(2018/07/15)
-
- BMS-200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro
-
BMS-200475, a never carbocyclic analog of 2'-deoxyguanosine, is a potent inhibitor of hepatitis B virus in vitro (ED50 = 3 nM) with relatively low cytotoxicity (CC50 = 21-120 μM). A practical 10-step asymmetric synthesis was developed affording BMS-200475 in 18% overall chemical yield and > 99% optical purity. The enantiomer of BMS-200475 as well as the adenine, thymine, and iodouracil analogs are much less active.
- Bisacchi,Chao,Bachard,Daris,Innaimo,Jacobs,Kocy,Lapointe,Martel,Merchant,Slusarchyk,Sundeen,Young,Colonno,Zahler
-
p. 127 - 132
(2007/10/03)
-
- Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
-
Antiviral activity is exhibited by compounds having the formula STR1 and its pharmaceutically acceptable salts.
- -
-
-